DJIA 17,712.66 34.43 0.19%
NASDAQ 4,891.22 27.86 0.57%
S&P 500 2,061.02 4.87 0.24%
market minute promo

Novartis (NYSE: NVS)

100.40 0.84 (0.84%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

NVS $100.40 0.84%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $99.91
Previous Close $99.56
Daily Range $99.85 - $100.60
52-Week Range $81.07 - $103.50
Market Cap $240.8B
P/E Ratio 26.91
Dividend (Yield) $2.82 (2.4%)
Ex-Dividend Date
Dividend Pay Date
Volume 1,133,213
Average Daily Volume 1,450,959
Current FY EPS $5.31




Drug Makers

Novartis (NVS) Description

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products. Website:

News & Commentary Rss Feed

3 Top Stocks for Obamacare Lovers

Love Obamacare? These stocks are right up your alley.

3 Little-Known Biotechs Working On Potential Blockbusters

These three biotechs have promising drugs in their pipelines that address billion dollar drug markets.

5 Freakishly Expensive Cancer Drugs

Prices for cancer medications are soaring.

7 of the Most Audacious 'Moonshot' Projects From Google, Amazon and Facebook

Ligand Pharmaceuticals: Biotech's Jack Of All Trades

Is It Time for GlaxoSmithKline plc to Change Management?

GlaxoSmithKline's share price has stagnated under CEO Andrew Witty. Is it time for a change?

Juno: Trying To Justify A $5.5B Valuation For A Year-Old Company

Is This The Biggest Threat to Isis Pharmaceuticals Stock?

Isis Pharmaceuticals has garnered a massive premium based on the potential of its antisense drug pipeline. With numerous companies entering the rare disease field, though, Isis' drugs might face stiff competition. So are investors being overly optimistic?

Novartis Reports Positive Data on Psoriasis Drug Cosentyx - Analyst Blog

11 Promising New Drugs Expected to Make Billions in Sales

See More NVS News...

NVS's Top Competitors

NVS $100.40 (0.84%)
Current stock: NVS
GSK $47.02 (0.77%)
Current stock: GSK
JNJ $100.34 (0.20%)
Current stock: JNJ
PFE $34.53 (1.08%)
Current stock: PFE